| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5824800 | Clinical Therapeutics | 2015 | 40 Pages |
Abstract
Apixaban was deemed to be dominant (less costly and more effective) versus low-dose edoxaban and a cost-effective alternative to high-dose edoxaban.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Gregory Y.H. MD, Tereza MSc, Thitima PhD, Hemant PhD, Corina MSc, Xianchen MD, PhD, Andreas PhD, Jack PhD, Paul MD,